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Abstract: Combinatorial drugs have been widely applied in disease treatment,
especially chemotherapy for cancer, due to its improved efficacy and reduced
toxicity compared with individual drugs. The study of combinatorial drugs re-
quires efficient experimental designs and proper follow-up statistical modelling
techniques. Linear and non-linear models are often used in the response surface
modelling for such experiments. We propose the use of Kriging models to better
depict the response surfaces of combinatorial drugs and take into account the
measurement error. We further study how proper experimental designs can re-
duce the required number of runs. We illustrate our method via a combinatorial
drug experiment on lung cancer. We demonstrate that only 27 runs are needed
to predict all 512 runs in the original experiment and achieve better precision
than existing analysis.
Key words and phrases : Combinatorial drugs, Design of experiment, Hill-based
models, Lung cancer, Neural network models, Polynomial models, Response sur-
face models.
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1 Introduction
Combination chemotherapy with multiple drugs have been widely applied in cancer therapy.
Such combinatorial drugs have enhanced efficacy and reduced toxicity due to multiple targets
and synergistic drug interactions (Devita et al. (1975), Lilenbaum et al. (2005) and Ning
et al. (2014)). Preclinical experiments in vitro are usually conducted to characterize the
pathological mechanisms and find the optimal drug combinations. In the analysis of these
experiments, different response surface modeling techniques are used to quantify the dose-
effect relationships. For economic reasons, the response surface model that requires less runs
and has better predictive power at the same time are preferred.
For combinatorial drugs with only two components, Hill models based on ray designs
(Chou (2006)) are popular in the analysis, but they are not suitable for multiple drug combi-
nations (Zhou and Xu (2014)). Polynomial (linear) models accompanied by full factorial or
fractional factorial designs are often used in analyzing multiple drug combinations (Jaynes
et al. (2013)), but their outputs are not bounded. In practice, many such experiments require
bounded responses, e.g. survival rate. The Hill-based (non-linear) model (Ning et al. (2014))
is a combination of Hill models and polynomial models, which overcome the shortcomings
of both. But, it is not stable in many situations. Neural networks can also be applied
(Al-Shyoukh et al. (2011)), but it require many data and the interpretations are hard.
In this paper, we propose the use of Kriging model, and show its superiority compared
with other modeling techniques in a combinatorial drug experiment on lung cancer. In
this experiment conducted by Al-Shyoukh et al. (2011), a 512-run, 8-level and 3-factor full
2
factorial design was applied to both normal cells and lung cancer cells. Ning et al. (2014)
analyzed the same experiment with the Hill-based model. In this paper, we show that the
Kriging model always performs the best dealing with various data sizes. Moreover, it can use
only 27 runs to predict all 512 runs with the highest accuracy, compared with the polynomial
model and Hill-based model using all 512 runs in Ning et al. (2014) and the neural network
using the recommended 80 runs in Al-Shyoukh et al. (2011). Kriging models are robust under
various experimental designs and can efficiently identify the drug interactions. Sensitivity
analysis can be done to select significant factors, and measurement errors are taken into
consideration in Kriging models.
This paper is organized as follows. In Section 2, we introduce four major response surface
modeling techniques. We illustrate Kriging models in details, and show the neural network
used in Al-Shyoukh et al. (2011) and the polynomial and Hill-based models used in Ning
et al. (2014). In Section 3, we compare these four models in analyzing the combinatorial
drug experiment on lung cancer which are used in both Al-Shyoukh et al. (2011) and Ning
et al. (2014). Section 4 concludes and discusses some future research.
2 Response surface modeling
2.1 The Kriging model
Originally from geosciences (Krige (1951)), Kriging models are now widely used in computer
experiments for optimization and sensitivity analysis. Computer experiments are popular in
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scientific researches and product developments to simulate real-world problems with complex
and deterministic computer codes. Kriging models can compensate for the effects of data
clustering and give better estimation of prediction error. In a Kriging model, the responses
are viewed as realizations of a Gaussian process, and the predicted response at a target
point can be represented as a weighted average of the responses at observed points. For an
introduction to Kriging models, see Sacks et al. (1989), Kleijnen (2009), Ginsbourger et al.
(2009) and Cressie (2015).
Different from the deterministic case in computer experiments, Kriging for random simu-
lations should be used in combinatorial drug experiments due to the existence of measurement
errors. It is desirable to adopt the following Ordinary Kriging (OK) model with a noise term
y(x) = µ+ Z(x) + , (1)
where y(x) is the response at point x, µ is the trend (or intercept), Z(x) is a Gaussian
process with zero mean and constant variance, and (x) ∼ N(0, τ 2) is independent of Z(x).
The covariance function for Z(x) is defined as:
φ(xi, xj) = cov(Z(xi), Z(xj)) = σ
2 ∗
d∏
l=1
Kl(h), (2)
where h = |xi,l − xj,l|, xi,l and xj,l are the lth elements of points (runs) xi and xj, d is
the dimensions (number of factors), σ2 is the variance parameter, and Kl(h) is the chosen
stationary correlation function. Two popular types of K(h) are:
Gauss: Kl(h) = exp(−1/2 ∗ (h/θl)2),
Mate´rn(ν = p+ 1/2) : Kl(h) = exp
(
−
√
2νh
θl
)
Γ(p+ 1)
Γ(2p+ 1)
p∑
i=0
(p+ i)!
i!(p− i!)
(√
8νh
θl
)p−i
,
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Figure 1: Examples of spatial correlation functions of Mate´rn family
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where p ∈ N+, θl is the range parameter which scales the correlation length, and Γ() is the
gamma function. The sample paths of z(x) with Gaussian correlation have derivatives at all
orders and are too smooth, which may cause numeric problems. Rasmussen and Williams
(2006) and Martin and Simpson (2005) recommended the use of Mate´rn correlation with ϑ =
5/2 whereKl(h) = (1+
√
5h/θl+5/3∗(h/θl)2)∗exp(−
√
5h/θl), and z(x) is twice differentiable.
Figure 1 shows the Mate´rn correlations (ϑ = 5/2) with different range parameters θ. With
smaller θ, the correlation decreases faster to zero as h increases. The parameters θl (l =
1, . . . , d) and σ2 in the correlation function can be estimated by maximizing a likelihood
function (MLE) based on the observed data. With the estimated parameters, the best linear
unbiased prediction on any point x is
ŷ(x) = µ̂+ γTC−1(y− µ̂1), (3)
where y is the response vector at n observed points x1, . . . , xn, µ̂ = (1
TC−11)−11TC−1y is
an estimate of µ, γ is the covariance vector (φ(x, x1), . . . , φ(x, xn))
T , matrix C = Φ + ∆,
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Φ is the variance-covariance matrix (φ(xi, xj))16i,j6n, ∆ is a diagonal matrix with diagonal
elements τ 2, and 1 is a column of n ones. From Equation 3, it’s easy to show that this
model does not interpolate all observed data due to the existence of measurement errors
(τ 2 6= 0). In the unreplicated experiment studied in Section 3, we assume a homogeneous
variance τ 2 = 0.0001 for the noise term, since the measurement is roughly accurate to 2
decimal places. Choosing τ 2 within the range 0.001 to 0.00001 does not make significant
difference in the model estimation. We adopt the R package “DiceKriging” (Roustant et al.
(2009)) to estimate the Kriging models in this paper.
2.2 Neural networks
Neural networks (McCulloch and Pitts (1943)) are widely used in machine learning, pattern
recognition, medical diagnosis and many other areas. An (artificial) neural network is based
on a collection of connected units called neurons, which receive input and produce output
via its network function. Neural network models are very flexible and it is generally hard
to determine the best network structures in practice. For a detailed introduction to neural
networks, see Livingstone (2008).
Al-Shyoukh et al. (2011) fitted a multilayer perceptron (shown in Figure 2) in analyzing
the combinatorial drug experiment. In this model, for the jth hidden neuron (j = 1, 2, 3, 4),
the network function is
f(x) =
1
1 + e−
∑
wi,jxi,j
,
Figure 2: A single hidden layer four-neuron multilayer perceptron
Drug 1
Drug 2
Drug 3
Response
Note: the bias nodes (with value 1) are not shown in this figure.
where wi,j are parameters to be estimated, x0,j = 1 and xi,j is the i
th input value (i = 1, 2, 3).
For the output neuron, g(x) =
∑
w
′
jx
′
j where w
′
j are parameters to be estimated, x
′
0 = 1
and x
′
j is the output from the j
th hidden neuron (j = 1, 2, 3, 4). Neural networks can be
estimated via resilient back-propagation method, and R package ”neuralnet” (Fritsch et al.
(2016)) is a current popular tool.
2.3 Polynomial and Hill-based models
Polynomial models are the most common analytic tools in drug experiments. In both Al-
Shyoukh et al. (2011) and Ning et al. (2014), the polynomial model in Equation 4 is used,
which includes all main, interaction and quadratic effects for the three drugs A,B and C.
y = β0 + β1A+ β2B + β3C + β4AB + β5AC + β6BC + β7A
2 + β8B
2 + β9C
2 +  . (4)
In vivo system, the dosage-effect relationship usually follows a sigmoidal curve (Chou
(2006)). Based on this, Ning et al. (2014) combined the polynomial and Hill models, and
proposed the Hill-based model:
y =
1
1 + ( c
IC50(θ)
)γ(θ)
+  , (5)
where the total dosage c = c1 + c2 + c3, and c1, c2 and c3 are the actual dosages of drugs
A, B and C, respectively; the dosage proportion θi = ci/c (i = 1, 2, 3); IC50(θ) = a0 +
a1θ1 + a2θ2 + a3θ1θ2 + a4θ
2
1 + a5θ
2
2; γ(θ) = b0 + b1θ1 + b2θ2 + b3θ1θ2 + b4θ
2
1 + b5θ
2
2. Function
IC50(θ) measures the dosage of the drug combination which yields 50% effect level, and γ(θ)
measures the changing rate of the smooth curve. Hill-based models are able to address all
drug combinations and characterize the interaction patterns. The responses from Hill-based
models are bounded within range 0 to 1.
3 Results and analysis
3.1 Drug combination experiment on Lung cancer
In this section, we focus on the drug combination experiment on lung cancer conducted by
Al-Shyoukh et al. (2011). Three drugs AG490(A), U0126(B) and indirubin-3
′
-monoxime (I-
3-M)(C) which are inhibitors targeting signaling pathways for cell survival and proliferation
were used, and a 512-run, 8-level full factorial design (Dfull) was applied to both normal cells
and lung cancer cells. The response variable is the ATP level (standardized to 0-1 range)
of the cell measured 72 hours after the drug treatments. The actual dosages for each drug
are given in Table 1 and coded as level 0 to 7. The purpose of this experiment is to model
the response surface and systematically quantify the characterization of cellular responses.
Table 1: Dose levels for each drug in the combinatorial experiment on lung cancer
Drug Dosage (µM)
AG490 (A) 0 0.3 1 3 10 30 100 300
U0126 (B) 0 0.1 0.3 1 3 10 30 100
I-3-M (C) 0 0.3 1 3 10 30 100 300
Coded level 0 1 2 3 4 5 6 7
An optimal combinatorial drug in this study should minimize the ATP levels of cancer cells
while keeping the ATP levels of normal cells above certain standards.
3.2 Model fitting and comparison
When comparing Kriging models, neural networks, polynomial models and Hill-based mod-
els, we consider four possible designs: the original 512-run 8-level full factorial design Dfull,
a 80-run random sub-design RD80, a 27-run random sub-design RD27, and a 27-run, 3-level
(coded levels 0, 4, 7 in Table 1) full factorial design D047. We use the actual dosages (stan-
dardized to 0-1 range) in all these design matrices. Given an n-run design, we fit a model
using n observations and use the model to predict all 512 observations. Then we compute
the mean square error (MSE) and correlations (r) based on the 512 predicted and actual
responses.
Tables 2 and 3 compares 1000 ×MSE(r) from different models and designs for normal
and cancer cells, respectively. “Neural network” is a single-layer four-neuron neural network
of which the result varies slightly each time running the R package ”neuralnet”. we select
the best result among 100 repetitions. Results for designs RD80 and RD27 are average
values from 100 random designs. When fitting Hill-based models with either RD80 or RD27,
numeric problems may occur, and we exclude them when calculating the average.
Table 2: Comparison of models and designs in fitting normal cell data
Dfull RD80 RD27 D047
Kriging 0.0018 (100.00%) 0.21(99.88%) 0.97(99.56%) 0.31(99.86%)
Neural network 0.11(99.95%) 1.28(99.37%) 3.52(98.43%) 2.99(98.61%)
Polynomial 0.48(99.75%) 1.16(99.42%) 3.65(98.39%) 1.12(99.49%)
Hill-based 0.89(99.10%) 1.07(99.49%) 3.57(98.30%) 3.30(98.39%)
Table 3: Comparison of models and designs in fitting cancer cell data
Dfull RD80 RD27 D047
Kriging 0.0030 (100.00%) 0.37(99.78%) 1.84(99.23%) 1.05(99.65%)
Neural network 0.27(99.88%) 1.57(99.34%) 3.97(98.43%) 2.98(99.16%)
Polynomial 2.98(98.67%) 6.77(97.09%) 39.82(87.74%) 5.84(97.66%)
Hill-based 1.42(98.80%) 1.67(99.33%) 4.99(97.93%) 4.70(97.92%)
From Tables 2 and 3, we can see that for both normal and cancer cells, Kriging models
are always the best in prediction (smallest MSEs and largest correlations) for all four types of
designs. In addition, Kriging models have the least number of parameters, and are suitable
for high dimension data. Note that when fitting Kriging, neural network, polynomial and
Hill-based models in this experiment, the numbers of parameters to be estimated are 5, 21,
10 and 12, respectively. In Table 4, we show the estimated parameters and their standard
deviations (SDs) for Kriging models along with designs Dfull and D047. All θ are significantly
different from 0, thus there is no identifiability issues. The SDs are computed from 1000
simulations.
Table 4: Estimations of ”parameters(SDs)” in Kriging models
Normal cells θA θB θC σ
2 trend
Dfull 1.24(0.11) 2.00(0.04) 1.24(0.12) 0.26(0.04) 0.62(0.06)
D047 1.11(0.22) 1.89(0.26) 1.08(0.22) 0.24(0.05) 0.54(0.10)
Cancer cells θA θB θC σ
2 trend
Dfull 0.98(0.11) 1.21(0.13) 0.52(0.06) 0.12(0.04) 0.39(0.04)
D047 0.83(0.20) 1.46(0.23) 0.41(0.10) 0.16(0.04) 0.37(0.06)
Using Kriging model, a small design can be sufficient in depicting the response surface.
From Tables 2 and 3, we can see that when using Kriging models and 27-run design D047,
the MSEs are as small as 3.10 ∗ 10−4 for normal cells and 1.05 ∗ 10−3 for cancer cells.
As a comparison, when using Hill-based models and 512-run design Dfull, the MSEs are
8.91 ∗ 10−4 and 1.42 ∗ 10−3; when using polynomial models and Dfull, the MSEs are 4.8 ∗
10−4 and 2.98 ∗ 10−3; when using neural networks and 80-run design RD80, the MSEs are
1.28 ∗ 10−3 and 1.57 ∗ 10−3, for normal and cancer cells, respectively. It’s clear that Kriging
models require the least number of runs and give the best predictions. The structured design
D047 outperforms the random design RD27, and is good enough in prediction under Kriging
models. In addition, design D047 is robust for all four types of models; while, designs RD80
and RD27 are unstable. When fitting Hill-based models with random 100 designs of RD80
and RD27, numeric problems occurred 6 and 35 times, respectively.
Figures 3 and 4 show the scatter-plots of predicted versus observed responses for all
four models with design D047. From the figures, we can see that Kriging models are the
best in prediction for both normal and cancer cells. Polynomial models perform well for
normal cells, but bad for cancer cells; neural networks perform bad for both cases and they
require larger designs to achieve accuracy; Hill-based models perform OK, but worse than
the Kriging models.
In order to study the drug interactions, we investigate and compare the contour plots
using Kriging models with designs Dfull and D047. Figures 5 and 6 show contour plots for any
two drugs while fixing the third to 0. We can see that for normal cells, Dfull and D047 perform
nearly the same for all drug combinations; for cancer cells, Dfull and D047 perform similarly
for A/B and B/C interactions, but slightly different for the A/C interaction. Furthermore,
for any two-drug combination, when both dosages are low, the lines are nearly straight,
which suggest no interactions; when both dosages are medium, the curves are convex, which
suggest synergism; when both dosages are high, curve patterns and their interactions vary by
cases. For example, for cancer cells, if we use the highest level of drug C only, the response
is 0.011; while, if we use the highest levels of both drugs B and C at the same time, the
response is 0.247, which shows clear antagonism. Note that synergism means the two drugs
Figure 3: Scatter-plots of predicted versus observed ATP levels on normal cells using design
D047.
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Figure 4: Scatter-plots of predicted versus observed ATP levels on cancer cells using design
D047.
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Figure 5: Contour plots of predicted ATP levels via Dfull and D047 under Kriging models
on normal cells.
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Figure 6: Contour plots of predicted ATP levels via Dfull and D047 under Kriging models
on cancer cells.
Dfull
A
B
 0.2 
 0.3 
 0.4 
 0.5 
 0.6 
 0.7 
 0.8 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
D047
A
B
 0.2  0.3 
 0.4 
 0.5 
 0.6 
 0.7 
 0.8 
 0.9 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Dfull
C
B
 0 
 0.1 
 0.2 
 0.3 
 0.4 
 0.5 
 0.6 
 0.7 
 0.8 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
D047
C
B
 
0.1 
 0.2 
 0.3 
 0.4 
 0.5 
 0.6 
 0.7 
 0.8 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Dfull
A
C
 0 
 0 
 0.1 
 0.2  0.3 
 0.4 
 0.5 
 0.6 
 0.7 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
D047
A
C
 0 
 0.1 
 0.2  0.3 
 0.4 
 0.5 
 0.6 
 0.7 
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
work cooperatively and antagonism means the two drugs inhibit each other.
4 Discussions
In this paper, we compare four major types of response surface models and four types of
designs in analyzing a combinatorial drug experiment by Al-Shyoukh et al. (2011). We find
that Kriging models need the least number of runs and give the best prediction. Design D047
is sufficient in this study, since the response measurement in this experiment is accurate to
2 decimal places and the root MSEs for Kriging models and D047 are 1.8% and 3.3% for
normal and cancer cells, respectively. It is also shown to be robust under different models
and good enough to analyze two-drug interactions. Note that if the coded levels (0,4,7)
rather than their corresponding actual dosages are used in the design matrix of D047, the
prediction MSEs are 0.016 and 0.012 for normal and cancer cells, which are much worse than
current results. The choice of small designs is not unique. Other 27-run full factorial designs
D057, D067 and 25-run uniform projection design (UPD25) can give similar or even better
results.
Due to the complexity of underlying biological systems, a systematic quantification of
effects for multiple drugs is challenging, and thus various models should be explored for such
experiments. In such situations, space-filling fractional factorial designs are ideal due to
their robustness Xiao (2015, 2017); Xiao and Xu (2017, 2018). Space-filling designs are also
ideal for Kriging models, since any unobserved point is close to some design points and so
the prediction error is small. An interesting topic for the future research is how space-filling
designs perform under Kriging models in drug combination studies.
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